Eisai has received FDA approval for the U.S. supply of the epilepsy drug Fycompa (perampanel) from its EMEA Knowledge Centre based in Hatfield, UK. The Hatfield site will manufacture six different strengths of tablets for the U.S. market. Eisai recently constructed a new 2,900m2 facility for the global packaging of potent compounds, which expands the current 7,800m2 Hatfield site by nearly 40%.   Gary Hendler, president and chief executive officer of Eisai EMEA, said, “The FDA approval for...